Phased Innovation Award for Exploratory Clinical Trials of Natural Products in NCCIH High Priority Research Topics (R21/R33)

The summary for the Phased Innovation Award for Exploratory Clinical Trials of Natural Products in NCCIH High Priority Research Topics (R21/R33) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Phased Innovation Award for Exploratory Clinical Trials of Natural Products in NCCIH High Priority Research Topics (R21/R33): The goal of this funding opportunity is to support pilot testing of natural products (i.e., botanicals, dietary supplements, and probiotics), which have sufficient early-stage data to justify further clinical testing of the product. Under this FOA, trials must be designed so that results, whether positive or negative, will provide information of high scientific utility and will support decisions about further development or testing of the natural product. The data collected should be used to fill gaps in scientific knowledge and provide the information necessary to develop a competitive full-scale clinical trial.

Support will be provided for up to two years (R21 phase) for milestone-driven bioavailability and pharmacokinetic testing and assessment of the natural products biological signature or mechanism of action. Based on the results of the R21 phase, this may be followed by support of up to 3 years (R33 phase) of support for further clinical studies of the natural product. This FOA is not appropriate for support of randomized clinical trials to test or determine efficacy. Ultimately, this R21/R33 funding mechanism is intended to speed the translation of emerging basic science findings about natural products into clinical pilot testing to determine whether continued clinical research is warranted.

Federal Grant Title:	Phased Innovation Award for Exploratory Clinical Trials of Natural Products in NCCIH High Priority Research Topics (R21/R33)
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-AT-16-001
Type of Funding:	Grant
CFDA Numbers:	93.213
CFDA Descriptions:	Research and Training in Complementary and Alternative Medicine
Current Application Deadline:	Jun 22, 2015
Original Application Deadline:	Jun 22, 2015
Posted Date:	Feb 6, 2015
Creation Date:	Feb 6, 2015
Archive Date:	Sep 4, 2015
Total Program Funding:	$1,000,000
Maximum Federal Grant Award:	none
Minimum Federal Grant Award:	none
Expected Number of Awards:
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Native American tribal governments (Federally recognized)
County governments
Others (see text field entitled "Additional Information on Eligibility" for clarification)
Small businesses
Special district governments
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Independent school districts
Public and State controlled institutions of higher education
For profit organizations other than small businesses
Private institutions of higher education
State governments
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
City or township governments
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Additional Information on Eligibility: Other Eligible Applicants include the following:
Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.
Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/rfa-files/RFA-AT-16-001.html
Grant Announcement Contact: NIH OER Webmaster [email protected]
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster

National Institutes of Health 301-496-3405
Similar Government Grants: • Feasibility Trials of the NIH Music-based Interventions Toolkit for Brain Disorders of Agi...; • Botanical Dietary Supplements Translational Research Teams (RM1 Clinical Trial Required); • Limited Competition: Research Resource for Natural Product Nuclear Magnetic Resonance Data...; • Leveraging Data at Scale to Understand Natural Product Impacts on Whole Person Health (R01...; • Natural Product Multi-Site Clinical Trial Data Coordinating Center (Collaborative U24 Clin...; • Probiotics for Pediatric Illnesses; • Cam Practitioner Research Education Project Grant Partnership; • Complementary and Alternative Medicine Career Transition Award (K22)
More Grants from the National Institutes of Health: • The NCI Worta McCaskill-Stevens Career Development Award for Community Oncology and Preven...; • Interventions to Reduce Sleep Health Disparities (R01 - Clinical Trials Optional); • Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement - Clinical Tri...; • Promoting Broad Participation in NIDCD's Extramural Workforce through Research Education E...; • HEAL Initiative-Early-Stage Discovery of New Pain Targets Within the Understudied Druggabl...